Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

NCT01639911 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Malignant Neoplasm of Breast
CNS Malignancy
Malignant Neoplasm of Gastrointestinal Tract
Genitourinary Neoplasms Malignancy and Gender Unspecified
Head and Neck Neoplasms
Melanoma
Malignant Neoplasm of Thorax

Interventions

DRUG: Alisertib
DRUG: Pazopanib

Sponsor

University of Illinois at Chicago

Collaborators

[object Object]